FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146165961> ?p ?o ?g. }

• W2146165961 endingPage "112" @default.
• W2146165961 startingPage "101" @default.
• W2146165961 abstract "The role of anticoagulation in patients with chronic heart failure has long been an area of interest and controversy. Traditionally the goal of anticoagulation has been to prevent embolic events, but recent trials also demonstrated that oral anticoagulation also prevents vascular events in patients with prior myocardial infarction, who constitute the majority of heart failure patients. Although antiplatelet agents also reduce postinfarction vascular events, few data are available in heart failure patients, and some evidence suggests that aspirin may also have the potential to worsen heart failure morbidity and mortality, possibly by interfering with the effects of angiotensin-converting enzyme inhibitors. Methods and results The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial was undertaken to determine the optimal antithrombotic agent for heart failure patients. WATCH was a prospective-randomized trial in which symptomatic heart failure patients in sinus rhythm with ejection fractions < or =35% taking angiotensin-converting enzyme inhibitors (unless not tolerated) and diuretics were randomized to open-label warfarin (target International Normalized Ratio 2.5-3.0) or double-blind antiplatelet therapy with aspirin 162 mg or clopidogrel 75 mg. Two primary comparisons were specified: anticoagulation with warfarin versus antiplatelet therapy with aspirin and antiplatelet therapy with clopidogrel versus antiplatelet therapy with aspirin. The primary outcome is the composite of death from all causes, nonfatal myocardial infarction, and nonfatal stroke analyzed as time to first event using the intent-to-treat approach. The secondary endpoint was the broader composite of death from all causes, nonfatal myocardial infarction, non-fatal stroke, and hospitalizations for worsening heart failure, unstable angina pectoris, and systemic or pulmonary artery embolic events. Additional prespecified analyses include heart failure events, coronary events, and resource utilization.Although the trial was designed to enter 4500 patients, it was terminated 18 months prematurely in June 2003 by the VA Cooperative Study Program because of poor enrollment with a resulting reduction of its power to achieve its original objective. This manuscript describes the study rationale, protocol design, and the baseline characteristics of the 1587 patients who were entered into the study. The WATCH trial will help define the optimal approach to antithrombotic therapy in the contemporary management of patients with chronic heart failure resulting from left ventricular systolic dysfunction." @default.
• W2146165961 created "2016-06-24" @default.
• W2146165961 creator A5015595507 @default.
• W2146165961 creator A5017160240 @default.
• W2146165961 creator A5026827724 @default.
• W2146165961 creator A5029533765 @default.
• W2146165961 creator A5037527199 @default.
• W2146165961 creator A5038862426 @default.
• W2146165961 creator A5040380335 @default.
• W2146165961 creator A5042766753 @default.
• W2146165961 creator A5046604104 @default.
• W2146165961 creator A5050936489 @default.
• W2146165961 creator A5077972812 @default.
• W2146165961 creator A5081943294 @default.
• W2146165961 creator A5082094092 @default.
• W2146165961 date "2004-04-01" @default.
• W2146165961 modified "2023-10-17" @default.
• W2146165961 title "The Warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): rationale, design, and baseline patient characteristics" @default.
• W2146165961 cites W1546597990 @default.
• W2146165961 cites W1600363276 @default.
• W2146165961 cites W1965524611 @default.
• W2146165961 cites W1967507355 @default.
• W2146165961 cites W1972074255 @default.
• W2146165961 cites W1979363567 @default.
• W2146165961 cites W1986836843 @default.
• W2146165961 cites W1989141371 @default.
• W2146165961 cites W1990978845 @default.
• W2146165961 cites W1991549653 @default.
• W2146165961 cites W1992530121 @default.
• W2146165961 cites W2004368795 @default.
• W2146165961 cites W2006835487 @default.
• W2146165961 cites W2017861990 @default.
• W2146165961 cites W2022631518 @default.
• W2146165961 cites W2024352468 @default.
• W2146165961 cites W2024372155 @default.
• W2146165961 cites W2039245972 @default.
• W2146165961 cites W2044694604 @default.
• W2146165961 cites W2046051565 @default.
• W2146165961 cites W2052386173 @default.
• W2146165961 cites W2052581447 @default.
• W2146165961 cites W2053844684 @default.
• W2146165961 cites W2061614070 @default.
• W2146165961 cites W2071686284 @default.
• W2146165961 cites W2075907190 @default.
• W2146165961 cites W2087093792 @default.
• W2146165961 cites W2089125087 @default.
• W2146165961 cites W2090326416 @default.
• W2146165961 cites W2091744415 @default.
• W2146165961 cites W2104756877 @default.
• W2146165961 cites W2118651999 @default.
• W2146165961 cites W2121637682 @default.
• W2146165961 cites W2139509479 @default.
• W2146165961 cites W2146191379 @default.
• W2146165961 cites W2163501806 @default.
• W2146165961 cites W2223980881 @default.
• W2146165961 cites W2259643956 @default.
• W2146165961 cites W2339002542 @default.
• W2146165961 cites W2339728422 @default.
• W2146165961 cites W311320695 @default.
• W2146165961 cites W4240342703 @default.
• W2146165961 cites W4244542018 @default.
• W2146165961 cites W42860337 @default.
• W2146165961 cites W70982661 @default.
• W2146165961 cites W94380503 @default.
• W2146165961 doi "https://doi.org/10.1016/j.cardfail.2004.02.006" @default.
• W2146165961 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15101020" @default.
• W2146165961 hasPublicationYear "2004" @default.
• W2146165961 type Work @default.
• W2146165961 sameAs 2146165961 @default.
• W2146165961 citedByCount "95" @default.
• W2146165961 countsByYear W21461659612012 @default.
• W2146165961 countsByYear W21461659612013 @default.
• W2146165961 countsByYear W21461659612014 @default.
• W2146165961 countsByYear W21461659612015 @default.
• W2146165961 countsByYear W21461659612016 @default.
• W2146165961 countsByYear W21461659612017 @default.
• W2146165961 countsByYear W21461659612021 @default.
• W2146165961 countsByYear W21461659612023 @default.
• W2146165961 crossrefType "journal-article" @default.
• W2146165961 hasAuthorship W2146165961A5015595507 @default.
• W2146165961 hasAuthorship W2146165961A5017160240 @default.
• W2146165961 hasAuthorship W2146165961A5026827724 @default.
• W2146165961 hasAuthorship W2146165961A5029533765 @default.
• W2146165961 hasAuthorship W2146165961A5037527199 @default.
• W2146165961 hasAuthorship W2146165961A5038862426 @default.
• W2146165961 hasAuthorship W2146165961A5040380335 @default.
• W2146165961 hasAuthorship W2146165961A5042766753 @default.
• W2146165961 hasAuthorship W2146165961A5046604104 @default.
• W2146165961 hasAuthorship W2146165961A5050936489 @default.
• W2146165961 hasAuthorship W2146165961A5077972812 @default.
• W2146165961 hasAuthorship W2146165961A5081943294 @default.
• W2146165961 hasAuthorship W2146165961A5082094092 @default.
• W2146165961 hasConcept C126322002 @default.
• W2146165961 hasConcept C127413603 @default.
• W2146165961 hasConcept C164705383 @default.
• W2146165961 hasConcept C168563851 @default.
• W2146165961 hasConcept C203092338 @default.
• W2146165961 hasConcept C2776301958 @default.

• next